Moreover, co-encapsulation of the invariant NKT cell agonist, together with the TLR 7/8 agonist R848 (Resiquimod) and polyI:C into PLGA nanoparticles enhanced CD4+ and CD8+ mediated anti-tumor responses mainly dependent on DC condition via NKT cells (159). Here, CD4 is linked to neoplasm.